Sorry, you need to enable JavaScript to visit this website.

Who we are

Beautiful woman celebrating individuality Galderma’s portfolio of aesthetic treatments such as dermal face fillers and injectables

A trusted and pioneering aesthetic partner for more than two decades

From the world’s first stabilized non-animal hyaluronic acid filler to the SmartClick syringe, Galderma has a long history of successfully supporting aesthetics professionals.


Embracing individuality and supporting practitioners

At Galderma, we believe that the things that make us individuals are the same things that make us beautiful. It’s a philosophy that we have taken through nearly 40 years of operation and more than two decades of providing world-leading aesthetic solutions.

Galderma produces both prescription medicines for the relief of debilitating skin diseases and aesthetic solutions that help individuals look and feel their best.

Our aesthetics business has long pioneered innovative solutions that empower individuals to express their own beauty. In 1996, we brought the world the first stabilized non-animal hyaluronic acid (HA) filler in the form of Restylane.

Other key milestones on our journey include:

• Introducing the first stabilized HA product for skin quality improvement (Skinboosters) in 2004; and

• Developing the SmartClick syringe in 2014, allowing clinicians to comfortably focus on technique rather than dose.

Today, respected clinicians worldwide relax, refine, refresh and renew patient faces with Galderma’s collagen stimulation and botulinum toxin products, and our range of skin boosters and fillers.

Galderma’s commitment is to work continuously to develop new, safe products, to help practitioners grow their knowledge and businesses, and to improve patient outcomes.

More than 40 million Restylane treatments carried out1

More than 85 million treatments carried out worldwide1,2,3

Over two decades of aesthetic innovation4,5

Innovation backed by science

Every product that Galderma sells and every claim we make is backed up by solid science. We know that you stake your reputation on the treatments you provide your patients. We stake ours on providing you reliable, scientifically proven products that deliver what they promise.
Satisfied patients

The world’s broadest portfolio of injectable technologies

Use the products in Galderma’s complementary range of aesthetic solutions alone or in combination to create the right result for every individual.

Relaxed beautiful smiling woman treated with botulinum toxin, find dermatologist near you. Galderma.
Relax facial muscles associated with frown lines and crow's feet to temporarily improve moderate to severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet lines).
Attractive young woman before and after treated for marionette lines and smile lines with Restylane dermal fillers from Galderma.

Refine facial features by lifting, filling and volumizing with Restylane, the world’s most diverse range of fillers.4,5 Galderma’s NASHA and OBT technologies provide the widest array of clinical options.


Refresh skin from within with the hyaluronic acid skin booster used in over 5.5 million clinical treatments.6 The SmartClick syringe helps you comfortably deliver the right dose.

Sculptra activate the power of your skin

Renew the skin7-13. Dermal fillers containing poly-L-lactic acid (PLLA) can stimulate the skin to produce more collagen, adding volume.

The trusted partner of choice for healthcare professionals worldwide

Building an aesthetics practice means delivering consistent, high-quality results to your patients. Galderma understands this. We provide clinicians worldwide with innovative aesthetic solutions supported by the latest science and training. Galderma’s key offerings include:

  • The world’s broadest collection of high-quality injectables;
  • Advanced technologies;
  • Ongoing professional education through GAIN.

Galderma delivers the world’s broadest collection of high-quality injectables, including trusted names like Restylane and Restylane Skinboosters.

Our products feature advanced NASHA and Optimal Balance Technology gels, providing you with the right combination of texture, particle size, and firmness for every application.

The Galderma Aesthetic Injector Network (GAIN), meanwhile, is a forum through which the world’s top aesthetics professionals are able to share their knowledge and expertise via physical training sessions, films, articles, and papers. 


Our approach to corporate social responsibility

Galderma works hard to provide its customers with the most advanced aesthetic technologies backed by science, and to ensure the best possible outcomes for patients. We also recognize our duty to care for and serve the wider community in which we operate through initiatives targeting areas including:

  • Sustainability;
  • Transparent, ethical dealings; and
  • Community development.

Our sustainability work includes solid, ongoing initiatives to better manage water, to address climate change and to reduce waste.

We encourage ethical behavior through initiatives including a Code of Ethics, a Global HCP Code to govern our dealings with healthcare professionals, and a Supplier Code that sets out our expectations of suppliers.

Our work in the community includes running the Galderma Aesthetic Injector Network allowing top aesthetics professionals to share their knowledge; our support for Camp Wonder, a summer camp for children with chronic and life-threatening skin diseases; and the provision of Derm101, a comprehensive digital resource, with content tailored to a range of healthcare professionals.

Learn more about how Galderma has evolved into being the trusted partner of choice for aesthetic healthcare professionals worldwide.


  1. Data on file (MA-39680)
  2. Data on file (MA-40221)
  3. Data on file (MA-39613)  
  4. Data on file (MA-33939).
  5. Öhrlund A. Poster presented at AMWC 2019.
  6. Data on file (MA-39929)
  7. Narins RS et al. J Am Acad Dermatol 2010;62(3):448–62.
  8. Brandt FS et al. Aesthet Surg J 2011;31(5):521–8.
  9. Nelson L and Stewart KJ. J Plast Reconstr Aesthet Surg 2012;65(4):439–47.
  10. Moyle GJ et al. HIV Med 2004;5(2):82–7.
  11. Mest DR and Humble G. Dermatol Surg 2006;32(11): 1336–45.
  12. Chen HH et al. JAMA Facial Plast Surg 2015;17(1):39–43.
  13. Valantin MA et al. AIDS 2003;17(17):2471–7.